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The CAMS study represents a substantial step forward, but not the
final one
C
annabinoids have been suggested
for the treatment of numerous
conditions, including cancer, vas-
cular, neurodegenerative, and inflam-
matory diseases.1 Probably because of
the nature of these substances, there is
considerable interest in these drugs
from the general public, lay media, and
politicians. Frequently, the translation
of scientific results is overly optimistic
and may have contributed to extensive
off label usage of cannabis among
chronically ill patients. The evidence
for therapeutic efficacy in humans is
not as yet convincing.
The CAMS study2 by Zajicek and
colleagues was the first large sympto-
matic trial of cannabinoids in multiple
sclerosis (MS). In this study, 630
patients with stable MS and muscle
spasticity were treated with delta-9-
tetrahydrocannabinol (THC), cannabis
extract or placebo. The main part of the
study (covering 15 weeks) is by far the
best designed study ever undertaken in
this field. There was no evidence of a
treatment effect on the primary out-
come, the Ashworth scale. The investi-
gators’ conclusion, however, was that
improvement in mobility and patients’
opinion of an improvement in pain
might be clinically useful.
In light of these results, the follow up
paper by Zajicek (see p 1664 of this
issue), presenting the data of a 12-
month, blinded, continuation phase, is
most welcome. It is the first study to
present longer term data on cannabi-
noids in MS. Although a small but
significant change in Ashworth score
was found in the THC group, the clinical
significance of this change remains
uncertain.
The authors discuss several sources of
bias; losses to follow up (around 20%),
discontinuation of medication after the
first phase (around 36%), and the
potential for unmasking. The success
of masking at the end of follow up is not
reported. Even though they discuss that
further unmasking was unlikely to
occur, the marked degree of unmasking
during the main study (up to 70%)
warrants cautious interpretation of the
results, in particular patient derived
outcome measures.
The trial was not designed to detect a
change in disease activity, but a reduc-
tion in relapse associated hospital
admissions was suggested during the
initial phase. This interesting finding
indicates that the anti-inflammatory
properties of cannabinoids might play
a favourable role in MS disease activity.3
However, if confined to relapses classi-
fied as serious adverse events, the
opposite trend was found during long
term follow up.
There were no major safety concerns
during the CAMS follow up. Never-
theless, several studies have shown that
there are deficits in the performance of
complex cognitive tasks in long term
cannabis users.4 Controversial is the
question of whether long term cannabis
use can cause irreversible deficits in
higher brain function that persist after
drug use ceases,4 especially in those
suffering from diseases such as MS,
who are already vulnerable for cognitive
decline. In addition, there has been a
long standing concern that cannabis use
might precipitate mental illness.4 In this
respect, final results from the CAMS
substudy on psychological and cognitive
functions are eagerly awaited.
The longer term data indicate that
orally administered cannabinoids may
hold therapeutic promise as an
approach to the treatment of MS related
symptoms. However, a balanced assess-
ment of the risk–benefit ratio for can-
nabinoids in MS is still difficult to
make. There is an urgent need for more
long term cannabinoid trials in MS
using carefully chosen outcome mea-
sures. These trials should also focus on
different cannabinoid products, includ-
ing the newer receptor agonists, and
different routes of administration. The
collection of scientifically sound data
will eventually lead to a justified clinical
use of cannabinoids, limit the extensive
off label usage, and guide the excited
scientific and political debate. In that
respect, the CAMS study represents a
substantial step forward, but not the
final one.
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